Ravandi, ., Stein, A., Erba, H., Lancet, J., Stein, E., Faderl, S., … Fathi, A. (2017). VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF. In HAEMATOLOGICA (Vol. 102, pp. 48–49). Madrid, SPAIN: FERRATA STORTI FOUNDATION.

Ravandi, M., A. Stein, H. Erba, J. Lancet, E. Stein, S. Faderl, R. Walter, et al. “VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF.” In HAEMATOLOGICA, 102:48–49. FERRATA STORTI FOUNDATION, 2017.

Ravandi, Stein A, Erba H, Lancet J, Stein E, Faderl S, et al. VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 48–9.

Ravandi, M., et al. “VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF.” HAEMATOLOGICA, vol. 102, FERRATA STORTI FOUNDATION, 2017, pp. 48–49.

Ravandi, Stein A, Erba H, Lancet J, Stein E, Faderl S, Walter R, Advani A, DeAngelo D, Kovacsovics T, Jillella A, Bixby D, Levy M, O’Meara M, Ho P, Fathi A. VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS: A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIAF. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 48–49.